Keros Therapeutics Inc (KROS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $11.19 (-1.50%), Market cap $0.20B, 52-week low–high $10.16 ~ $21.84.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The comp
Financial statements, price targets, institutional (13F) holdings and related news for Keros Therapeutics Inc are updated in real time on BlackAll Trade.
Keros Therapeutics Inc trades at $11.19 (-1.50%). Real-time quotes and charts are available on BlackAll Trade.
Keros Therapeutics Inc has a market cap of about $0.20B.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transform